Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2023-2029

Page: 100

Published Date: 06 Sep 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Idiopathic Pulmonary Fibrosis (IPF) Drug market size is expected to reach $ 393.2 million by 2029, rising at a market growth of 4.0% CAGR during the forecast period (2023-2029).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.

This report studies the global Idiopathic Pulmonary Fibrosis (IPF) Drug production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Idiopathic Pulmonary Fibrosis (IPF) Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Idiopathic Pulmonary Fibrosis (IPF) Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Idiopathic Pulmonary Fibrosis (IPF) Drug total production and demand, 2018-2029, (K Units)
Global Idiopathic Pulmonary Fibrosis (IPF) Drug total production value, 2018-2029, (USD Million)
Global Idiopathic Pulmonary Fibrosis (IPF) Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Idiopathic Pulmonary Fibrosis (IPF) Drug consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug domestic production, consumption, key domestic manufacturers and share
Global Idiopathic Pulmonary Fibrosis (IPF) Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Idiopathic Pulmonary Fibrosis (IPF) Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Idiopathic Pulmonary Fibrosis (IPF) Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global Idiopathic Pulmonary Fibrosis (IPF) Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include American Lung Association, Roche, Genentech, Fierce Pharma, FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova and Novartis, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Idiopathic Pulmonary Fibrosis (IPF) Drug market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market, Segmentation by Type
    Nintedanib
    Pirfenidone

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market, Segmentation by Application
    Hospital
    Clinics
    Others

Companies Profiled:
    American Lung Association
    Roche
    Genentech
    Fierce Pharma
    FibroGen
    United Therapeutics
    Bellerophon Therapeutics
    MediciNova
    Novartis

Key Questions Answered
1. How big is the global Idiopathic Pulmonary Fibrosis (IPF) Drug market?
2. What is the demand of the global Idiopathic Pulmonary Fibrosis (IPF) Drug market?
3. What is the year over year growth of the global Idiopathic Pulmonary Fibrosis (IPF) Drug market?
4. What is the production and production value of the global Idiopathic Pulmonary Fibrosis (IPF) Drug market?
5. Who are the key producers in the global Idiopathic Pulmonary Fibrosis (IPF) Drug market?

Table of Contents

1 Supply Summary
    1.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Introduction
    1.2 World Idiopathic Pulmonary Fibrosis (IPF) Drug Supply & Forecast
        1.2.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value (2018 & 2022 & 2029)
        1.2.2 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029)
        1.2.3 World Idiopathic Pulmonary Fibrosis (IPF) Drug Pricing Trends (2018-2029)
    1.3 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Region (Based on Production Site)
        1.3.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Region (2018-2029)
        1.3.2 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Region (2018-2029)
        1.3.3 World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2018-2029)
        1.3.4 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029)
        1.3.5 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029)
        1.3.6 China Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029)
        1.3.7 Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Major Market Trends

2 Demand Summary
    2.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Demand (2018-2029)
    2.2 World Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption by Region
        2.2.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption by Region (2018-2023)
        2.2.2 World Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Forecast by Region (2024-2029)
    2.3 United States Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029)
    2.4 China Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029)
    2.5 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029)
    2.6 Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029)
    2.7 South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029)
    2.8 ASEAN Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029)
    2.9 India Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029)

3 World Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers Competitive Analysis
    3.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Manufacturer (2018-2023)
    3.2 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Manufacturer (2018-2023)
    3.3 World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Manufacturer (2018-2023)
    3.4 Idiopathic Pulmonary Fibrosis (IPF) Drug Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Idiopathic Pulmonary Fibrosis (IPF) Drug in 2022
        3.5.3 Global Concentration Ratios (CR8) for Idiopathic Pulmonary Fibrosis (IPF) Drug in 2022
    3.6 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Overall Company Footprint Analysis
        3.6.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Region Footprint
        3.6.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Type Footprint
        3.6.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Comparison
        4.1.1 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Production Comparison
        4.2.1 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Comparison
        4.3.1 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2023)
    4.5 China Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers and Market Share
        4.5.1 China Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value (2018-2023)
        4.5.3 China Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2023)
    4.6 Rest of World Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2023)

5 Market Analysis by Type
    5.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Nintedanib
        5.2.2 Pirfenidone
    5.3 Market Segment by Type
        5.3.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Type (2018-2029)
        5.3.2 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Type (2018-2029)
        5.3.3 World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Clinics
        6.2.3 Others
    6.3 Market Segment by Application
        6.3.1 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Application (2018-2029)
        6.3.2 World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Application (2018-2029)
        6.3.3 World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2018-2029)

7 Company Profiles
    7.1 American Lung Association
        7.1.1 American Lung Association Details
        7.1.2 American Lung Association Major Business
        7.1.3 American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.1.4 American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 American Lung Association Recent Developments/Updates
        7.1.6 American Lung Association Competitive Strengths & Weaknesses
    7.2 Roche
        7.2.1 Roche Details
        7.2.2 Roche Major Business
        7.2.3 Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.2.4 Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 Roche Recent Developments/Updates
        7.2.6 Roche Competitive Strengths & Weaknesses
    7.3 Genentech
        7.3.1 Genentech Details
        7.3.2 Genentech Major Business
        7.3.3 Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.3.4 Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 Genentech Recent Developments/Updates
        7.3.6 Genentech Competitive Strengths & Weaknesses
    7.4 Fierce Pharma
        7.4.1 Fierce Pharma Details
        7.4.2 Fierce Pharma Major Business
        7.4.3 Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.4.4 Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 Fierce Pharma Recent Developments/Updates
        7.4.6 Fierce Pharma Competitive Strengths & Weaknesses
    7.5 FibroGen
        7.5.1 FibroGen Details
        7.5.2 FibroGen Major Business
        7.5.3 FibroGen Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.5.4 FibroGen Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 FibroGen Recent Developments/Updates
        7.5.6 FibroGen Competitive Strengths & Weaknesses
    7.6 United Therapeutics
        7.6.1 United Therapeutics Details
        7.6.2 United Therapeutics Major Business
        7.6.3 United Therapeutics Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.6.4 United Therapeutics Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 United Therapeutics Recent Developments/Updates
        7.6.6 United Therapeutics Competitive Strengths & Weaknesses
    7.7 Bellerophon Therapeutics
        7.7.1 Bellerophon Therapeutics Details
        7.7.2 Bellerophon Therapeutics Major Business
        7.7.3 Bellerophon Therapeutics Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.7.4 Bellerophon Therapeutics Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.7.5 Bellerophon Therapeutics Recent Developments/Updates
        7.7.6 Bellerophon Therapeutics Competitive Strengths & Weaknesses
    7.8 MediciNova
        7.8.1 MediciNova Details
        7.8.2 MediciNova Major Business
        7.8.3 MediciNova Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.8.4 MediciNova Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.8.5 MediciNova Recent Developments/Updates
        7.8.6 MediciNova Competitive Strengths & Weaknesses
    7.9 Novartis
        7.9.1 Novartis Details
        7.9.2 Novartis Major Business
        7.9.3 Novartis Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
        7.9.4 Novartis Idiopathic Pulmonary Fibrosis (IPF) Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.9.5 Novartis Recent Developments/Updates
        7.9.6 Novartis Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Chain
    8.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Upstream Analysis
        8.2.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Core Raw Materials
        8.2.2 Main Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Idiopathic Pulmonary Fibrosis (IPF) Drug Production Mode
    8.6 Idiopathic Pulmonary Fibrosis (IPF) Drug Procurement Model
    8.7 Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Sales Model and Sales Channels
        8.7.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Model
        8.7.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share by Region (2018-2023)
    Table 5. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share by Region (2024-2029)
    Table 6. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Region (2018-2023) & (K Units)
    Table 7. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Region (2024-2029) & (K Units)
    Table 8. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share by Region (2018-2023)
    Table 9. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share by Region (2024-2029)
    Table 10. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2018-2023) & (US$/Unit)
    Table 11. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2024-2029) & (US$/Unit)
    Table 12. Idiopathic Pulmonary Fibrosis (IPF) Drug Major Market Trends
    Table 13. World Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
    Table 14. World Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption by Region (2018-2023) & (K Units)
    Table 15. World Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Forecast by Region (2024-2029) & (K Units)
    Table 16. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Idiopathic Pulmonary Fibrosis (IPF) Drug Producers in 2022
    Table 18. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Manufacturer (2018-2023) & (K Units)
    Table 19. Production Market Share of Key Idiopathic Pulmonary Fibrosis (IPF) Drug Producers in 2022
    Table 20. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 21. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Company Evaluation Quadrant
    Table 22. World Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Idiopathic Pulmonary Fibrosis (IPF) Drug Production Site of Key Manufacturer
    Table 24. Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Type Footprint
    Table 25. Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Application Footprint
    Table 26. Idiopathic Pulmonary Fibrosis (IPF) Drug Competitive Factors
    Table 27. Idiopathic Pulmonary Fibrosis (IPF) Drug New Entrant and Capacity Expansion Plans
    Table 28. Idiopathic Pulmonary Fibrosis (IPF) Drug Mergers & Acquisitions Activity
    Table 29. United States VS China Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Idiopathic Pulmonary Fibrosis (IPF) Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 31. United States VS China Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 32. United States Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2023) & (K Units)
    Table 36. United States Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share (2018-2023)
    Table 37. China Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2023) & (K Units)
    Table 41. China Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share (2018-2023)
    Table 42. Rest of World Based Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2023) & (K Units)
    Table 46. Rest of World Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share (2018-2023)
    Table 47. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Type (2018-2023) & (K Units)
    Table 49. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Type (2024-2029) & (K Units)
    Table 50. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2018-2023) & (US$/Unit)
    Table 53. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2024-2029) & (US$/Unit)
    Table 54. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Application (2018-2023) & (K Units)
    Table 56. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production by Application (2024-2029) & (K Units)
    Table 57. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2018-2023) & (US$/Unit)
    Table 60. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2024-2029) & (US$/Unit)
    Table 61. American Lung Association Basic Information, Manufacturing Base and Competitors
    Table 62. American Lung Association Major Business
    Table 63. American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 64. American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. American Lung Association Recent Developments/Updates
    Table 66. American Lung Association Competitive Strengths & Weaknesses
    Table 67. Roche Basic Information, Manufacturing Base and Competitors
    Table 68. Roche Major Business
    Table 69. Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 70. Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. Roche Recent Developments/Updates
    Table 72. Roche Competitive Strengths & Weaknesses
    Table 73. Genentech Basic Information, Manufacturing Base and Competitors
    Table 74. Genentech Major Business
    Table 75. Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 76. Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. Genentech Recent Developments/Updates
    Table 78. Genentech Competitive Strengths & Weaknesses
    Table 79. Fierce Pharma Basic Information, Manufacturing Base and Competitors
    Table 80. Fierce Pharma Major Business
    Table 81. Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 82. Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. Fierce Pharma Recent Developments/Updates
    Table 84. Fierce Pharma Competitive Strengths & Weaknesses
    Table 85. FibroGen Basic Information, Manufacturing Base and Competitors
    Table 86. FibroGen Major Business
    Table 87. FibroGen Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 88. FibroGen Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. FibroGen Recent Developments/Updates
    Table 90. FibroGen Competitive Strengths & Weaknesses
    Table 91. United Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 92. United Therapeutics Major Business
    Table 93. United Therapeutics Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 94. United Therapeutics Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 95. United Therapeutics Recent Developments/Updates
    Table 96. United Therapeutics Competitive Strengths & Weaknesses
    Table 97. Bellerophon Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 98. Bellerophon Therapeutics Major Business
    Table 99. Bellerophon Therapeutics Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 100. Bellerophon Therapeutics Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 101. Bellerophon Therapeutics Recent Developments/Updates
    Table 102. Bellerophon Therapeutics Competitive Strengths & Weaknesses
    Table 103. MediciNova Basic Information, Manufacturing Base and Competitors
    Table 104. MediciNova Major Business
    Table 105. MediciNova Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 106. MediciNova Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. MediciNova Recent Developments/Updates
    Table 108. Novartis Basic Information, Manufacturing Base and Competitors
    Table 109. Novartis Major Business
    Table 110. Novartis Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services
    Table 111. Novartis Idiopathic Pulmonary Fibrosis (IPF) Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 112. Global Key Players of Idiopathic Pulmonary Fibrosis (IPF) Drug Upstream (Raw Materials)
    Table 113. Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Customers
    Table 114. Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Distributors
List of Figure
    Figure 1. Idiopathic Pulmonary Fibrosis (IPF) Drug Picture
    Figure 2. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029) & (K Units)
    Figure 5. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price (2018-2029) & (US$/Unit)
    Figure 6. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share by Region (2018-2029)
    Figure 7. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share by Region (2018-2029)
    Figure 8. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029) & (K Units)
    Figure 9. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029) & (K Units)
    Figure 10. China Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029) & (K Units)
    Figure 11. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Production (2018-2029) & (K Units)
    Figure 12. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029) & (K Units)
    Figure 15. World Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Market Share by Region (2018-2029)
    Figure 16. United States Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029) & (K Units)
    Figure 17. China Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029) & (K Units)
    Figure 18. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029) & (K Units)
    Figure 19. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029) & (K Units)
    Figure 20. South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029) & (K Units)
    Figure 21. ASEAN Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029) & (K Units)
    Figure 22. India Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption (2018-2029) & (K Units)
    Figure 23. Producer Shipments of Idiopathic Pulmonary Fibrosis (IPF) Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Idiopathic Pulmonary Fibrosis (IPF) Drug Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Idiopathic Pulmonary Fibrosis (IPF) Drug Markets in 2022
    Figure 26. United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share 2022
    Figure 30. China Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share 2022
    Figure 32. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share by Type in 2022
    Figure 34. Nintedanib
    Figure 35. Pirfenidone
    Figure 36. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share by Type (2018-2029)
    Figure 37. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share by Type (2018-2029)
    Figure 38. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2018-2029) & (US$/Unit)
    Figure 39. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 40. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share by Application in 2022
    Figure 41. Hospital
    Figure 42. Clinics
    Figure 43. Others
    Figure 44. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Market Share by Application (2018-2029)
    Figure 45. World Idiopathic Pulmonary Fibrosis (IPF) Drug Production Value Market Share by Application (2018-2029)
    Figure 46. World Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2018-2029) & (US$/Unit)
    Figure 47. Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Chain
    Figure 48. Idiopathic Pulmonary Fibrosis (IPF) Drug Procurement Model
    Figure 49. Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Model
    Figure 50. Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Channels, Direct Sales, and Distribution
    Figure 51. Methodology
    Figure 52. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

American Lung Association
Roche
Genentech
Fierce Pharma
FibroGen
United Therapeutics
Bellerophon Therapeutics
MediciNova
Novartis

Related Reports

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 06 Sep 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at USD 298.4 million in 2022 and is forecast to a readjusted size of USD 393.2 million by 2029 with a CAGR of 4.0% during review period.

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 29 Feb 2024

date Pharma & Healthcare

These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2024-2030

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2024-2030

date 29 Feb 2024

date Pharma & Healthcare

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

date 13 Jan 2025

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at US$ 301 million in 2024 and is forecast to a readjusted size of USD 398 million by 2031 with a CAGR of 4.1% during review period.

Product Tags

Idiopathic Pulmonary Fibrosis (IPF) Drug

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>